Invivyd (NASDAQ:IVVD) Receives Buy Rating from HC Wainwright

Invivyd (NASDAQ:IVVD - Get Free Report)'s stock had its "buy" rating reaffirmed by stock analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They presently have a $10.00 price objective on the stock.

Separately, D. Boral Capital restated a "buy" rating and issued a $9.00 price target on shares of Invivyd in a research note on Thursday, March 20th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $7.89.

Invivyd Trading Down 1.6 %

Shares of NASDAQ IVVD traded down $0.01 during midday trading on Wednesday, reaching $0.60. 1,811,748 shares of the company were exchanged, compared to its average volume of 4,238,549. The stock has a fifty day simple moving average of $1.00 and a 200 day simple moving average of $0.86. The stock has a market cap of $71.98 million, a P/E ratio of -0.31 and a beta of 0.09. Invivyd has a 1 year low of $0.35 and a 1 year high of $4.74.

Invivyd (NASDAQ:IVVD - Get Free Report) last released its earnings results on Thursday, March 20th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.25) by $0.10. The company had revenue of $13.80 million during the quarter, compared to analyst estimates of $13.57 million. As a group, analysts forecast that Invivyd will post -1.64 earnings per share for the current year.

Insider Activity at Invivyd

In other news, Director Terrance Mcguire sold 86,545 shares of Invivyd stock in a transaction on Monday, December 30th. The stock was sold at an average price of $0.48, for a total transaction of $41,541.60. Following the completion of the transaction, the director now owns 3,170,231 shares of the company's stock, valued at $1,521,710.88. The trade was a 2.66 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 17.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Invivyd

Large investors have recently added to or reduced their stakes in the business. State Street Corp grew its position in shares of Invivyd by 3.7% in the third quarter. State Street Corp now owns 1,018,640 shares of the company's stock valued at $1,039,000 after purchasing an additional 35,904 shares during the last quarter. Barclays PLC lifted its stake in Invivyd by 179.6% in the 3rd quarter. Barclays PLC now owns 117,973 shares of the company's stock valued at $120,000 after buying an additional 75,780 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in Invivyd by 644.1% during the 4th quarter. JPMorgan Chase & Co. now owns 256,900 shares of the company's stock valued at $114,000 after buying an additional 222,375 shares during the last quarter. Renaissance Technologies LLC purchased a new position in Invivyd during the fourth quarter worth $74,000. Finally, Jane Street Group LLC raised its holdings in shares of Invivyd by 290.5% in the fourth quarter. Jane Street Group LLC now owns 117,432 shares of the company's stock worth $52,000 after acquiring an additional 87,358 shares during the last quarter. 70.36% of the stock is owned by institutional investors and hedge funds.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.